Entrada Therapeutics, Inc. (TRDA) Ownership
TRDA ownership summary
as of October 18, 2026- Institutions
- 82.2% of shares outstanding
- Insiders
- 12.23% of shares outstanding
- Shares outstanding
- 38.9M
- Float
- 22.7M shares available to trade
- Short interest
- 11.91% 3.0M shares short
- Days to cover
- 8.99 short interest up 8.9% vs prior month
- Institutions 82.22%
- Insiders 12.23%
- Other investors 5.55%
TRDA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Baker Bros Advisors LP | 13.03% | 5.1M | $22.2M | — | June 30, 2026 |
| 2 | 5AM Venture Management, LLC | 10.42% | 4.1M | $17.7M | — | June 30, 2026 |
| 3 | BlackRock Inc | 6.63% | 2.6M | $11.3M | +224,540 (+9.5%) | June 30, 2026 |
| 4 | Merck & Co Inc | 4.47% | 1.7M | $7.6M | +1.7M (0.0%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.26% | 1.3M | $5.5M | +13,621 (+1.1%) | June 30, 2026 |
| 6 | MPM Oncology Impact Management LP | 3.22% | 1.3M | $5.5M | +1.3M (0.0%) | June 30, 2026 |
| 7 | TCG Crossover Management, LLC | 2.72% | 1.1M | $4.6M | −1.2M (−53.7%) | June 30, 2026 |
| 8 | Wellington Management Company LLP | 2.45% | 954K | $4.2M | −80,363 (−7.8%) | June 30, 2026 |
| 9 | Millennium Management LLC | 1.96% | 764K | $3.3M | +244,603 (+47.1%) | June 30, 2026 |
| 10 | StepStone Group LLC | 1.96% | 761K | $3.3M | — | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 1.84% | 717K | $3.1M | +50,083 (+7.5%) | June 30, 2026 |
| 12 | AQR Capital Management LLC | 1.80% | 700K | $3.1M | +620,044 (+780.0%) | June 30, 2026 |
| 13 | Nantahala Capital Management, LLC | 1.54% | 601K | $2.6M | +441,818 (+277.3%) | June 30, 2026 |
| 14 | State Street Corp | 1.53% | 597K | $2.6M | +62,879 (+11.8%) | June 30, 2026 |
| 15 | T. Rowe Price Associates, Inc. | 1.39% | 542K | $2.4M | +16,273 (+3.1%) | June 30, 2026 |
| 16 | JPMorgan Chase & Co | 1.27% | 496K | $2.2M | +481,610 (+3,243.8%) | June 30, 2026 |
| 17 | Acadian Asset Management LLC | 1.03% | 401K | $1.8M | +67,693 (+20.3%) | June 30, 2026 |
| 18 | Citadel Advisors Llc | 1.01% | 394K | $1.7M | +179,305 (+83.4%) | June 30, 2026 |
| 19 | Dimensional Fund Advisors, Inc. | 0.97% | 376K | $1.6M | +51,665 (+15.9%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.80% | 310K | $1.4M | +74,950 (+31.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 5.5M shares and 2 cut 1.3M.
TRDA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.45% | 954K | $4.2M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.98% | 772K | $3.4M | −8,896 (−1.1%) | September 30, 2026 |
| 3 | MEDICAL BioHealth EUR Acc | 1.17% | 455K | $2.0M | +96 (+0.0%) | August 31, 2026 |
| 4 | Fidelity Small Cap Index | 0.83% | 322K | $1.4M | +3,055 (+1.0%) | July 31, 2026 |
| 5 | iShares Russell 2000 Value ETF | 0.75% | 293K | $1.3M | +444 (+0.2%) | September 30, 2026 |
| 6 | iShares Biotechnology ETF | 0.48% | 186K | $813,908 | −1,408 (−0.8%) | September 30, 2026 |
| 7 | JPMorgan US Small Company L | 0.45% | 176K | $769,854 | +4,556 (+2.7%) | August 31, 2026 |
| 8 | Vanguard Russell 2000 ETF | 0.45% | 174K | $761,739 | +4,829 (+2.8%) | September 30, 2026 |
| 9 | Schwab US Small-Cap ETF™ | 0.37% | 142K | $622,594 | +90 (+0.1%) | September 30, 2026 |
| 10 | BSF Systematic US Eq Abs Ret A2 USD | 0.34% | 134K | $587,000 | +4,729 (+3.6%) | December 31, 2025 |
| 11 | RIM Global Bioscience EUR | 0.33% | 129K | $563,153 | — | June 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.32% | 125K | $547,063 | +8,439 (+7.2%) | August 31, 2026 |
| 13 | iShares Micro-Cap ETF | 0.24% | 94K | $411,322 | −649 (−0.7%) | September 30, 2026 |
| 14 | Allspring Disciplined Small Cap Inst | 0.20% | 80K | $347,730 | +15,538 (+24.3%) | September 30, 2026 |
| 15 | DFA US Micro Cap I | 0.20% | 77K | $337,058 | +14,741 (+23.6%) | August 31, 2026 |
| 16 | Dimensional US Small Cap ETF | 0.19% | 72K | $315,807 | — | September 30, 2026 |
| 17 | Schwab Small Cap Index | 0.18% | 72K | $314,408 | — | August 31, 2026 |
| 18 | Avantis US Small Cap Equity ETF | 0.17% | 68K | $295,504 | — | September 30, 2026 |
| 19 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.17% | 66K | $288,298 | −4,612 (−6.5%) | September 30, 2026 |
| 20 | iShares Russell 2000 Small-Cap Idx Instl | 0.15% | 58K | $255,199 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TRDA insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Kory James Wentworth | Sell | $12.95 | 2,500 | $32,375 |
| 2026-03-10 | Kory James Wentworth | Sell | $13.02 | 11,388 | $148,272 |
| 2026-03-10 | Nathan J Dowden | Sell | $13.05 | 11,894 | $155,217 |
| 2026-03-09 | Kory James Wentworth | Sell | $13.00 | 5,089 | $66,157 |
| 2026-03-09 | Nathan J Dowden | Sell | $13.02 | 3,116 | $40,570 |
| 2026-03-04 | Kory James Wentworth | Sell | $12.25 | 7,988 | $97,853 |
| 2025-11-21 | Kory James Wentworth | Sell | $9.98 | 8,910 | $88,922 |
| 2025-11-14 | Kush Parmar | Sell | $8.80 | 200,000 | $1.8M |
| 2025-11-14 | Ventures V L.P. 5Am | Sell | $8.80 | 200,000 | $1.8M |
| 2025-11-12 | Bros. Advisors Lp Baker | Buy | $7.76 | 100,736 | $781,711 |
| 2025-11-11 | Bros. Advisors Lp Baker | Buy | $7.50 | 46,434 | $348,255 |
| 2025-11-10 | Bros. Advisors Lp Baker | Buy | $7.21 | 30,874 | $222,602 |
| 2025-07-09 | Kush Parmar | Sell | $7.50 | 27,000 | $202,500 |
| 2025-07-09 | Ventures V L.P. 5Am | Sell | $7.50 | 20,065 | $150,488 |
| 2025-07-09 | Ventures V L.P. 5Am | Sell | $7.50 | 6,935 | $52,012 |
| 2025-06-30 | Kush Parmar | Sell | $6.81 | 25,000 | $170,250 |
| 2025-06-30 | Ventures V L.P. 5Am | Sell | $6.81 | 18,578 | $126,516 |
| 2025-06-30 | Ventures V L.P. 5Am | Sell | $6.81 | 6,422 | $43,734 |
| 2025-06-27 | Kush Parmar | Sell | $6.91 | 75,000 | $518,250 |
| 2025-06-27 | Ventures V L.P. 5Am | Sell | $6.91 | 55,735 | $385,129 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TRDA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TRDA
Institutional investors own 82.2% of Entrada Therapeutics's shares and insiders 12.23%. The largest holder is Baker Bros Advisors LP with 13.03% of the shares (5.1M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 2 reduced their stake in the latest filings. Short interest is 11.91% of the float, or 8.99 days of average trading volume. The share count rose 4,037.1% since 2019.
Related: TRDA analyst forecast, TRDA key metrics. See the TRDA stock overview for the latest quote and news.
TRDA ownership FAQ
Who owns the most Entrada Therapeutics stock?
The largest shareholders of Entrada Therapeutics are Baker Bros Advisors LP (13.03%), 5AM Venture Management, LLC (10.42%), BlackRock Inc (6.63%), Merck & Co Inc (4.47%), Vanguard Capital Management, LLC (3.26%).
What percentage of Entrada Therapeutics is owned by institutions?
Institutions hold 82.2% of Entrada Therapeutics's shares outstanding; insiders hold 12.23%.
Which funds own Entrada Therapeutics?
The largest fund holders of Entrada Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.45%), iShares Russell 2000 ETF (1.98%), MEDICAL BioHealth EUR Acc (1.17%), Fidelity Small Cap Index (0.83%), iShares Russell 2000 Value ETF (0.75%).
What is Entrada Therapeutics's short interest?
3.0M shares of Entrada Therapeutics were sold short, 11.91% of the float; at the average daily volume it would take 8.99 days to cover.
Are insiders buying or selling Entrada Therapeutics?
Of the latest 20 reported insider transactions in Entrada Therapeutics (since June 27, 2025), 3 were purchases and 17 were sales.
How many shares of Entrada Therapeutics are outstanding?
Entrada Therapeutics has 38.9M shares outstanding, of which 22.7M are in the public float.